| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = -$340,069 ) |
| | 2023 | 2020 | BIOSTAGE, INC. | 84 OCTOBER HILL RD STE 11 | HOLLISTON | MA | 01746-1371 | MIDDLESEX | USA | R44HD095784 | A retrievable autologous bioengineered esophageal implant as a novel treatment for long-gap esophageal atresia | 000 | 3 | NIH | 10/24/2022 | -$340,069 |
|
| Issue Date FY: 2020 ( Subtotal = $498,749 ) |
| | 2020 | 2020 | BIOSTAGE, INC. | 84 OCTOBER HILL RD STE 11 | HOLLISTON | MA | 01746-1371 | MIDDLESEX | USA | R44HD095784 | A retrievable autologous bioengineered esophageal implant as a novel treatment for long-gap esophageal atresia | 002 | 3 | NIH | 8/3/2020 | $498,749 |
| | 2020 | 2019 | BIOSTAGE, INC. | 84 OCTOBER HILL RD STE 11 | HOLLISTON | MA | 01746-1371 | MIDDLESEX | USA | R44HD095784 | A retrievable autologous bioengineered esophageal implant as a novel treatment for long-gap esophageal atresia | 001 | 2 | NIH | 1/23/2020 | $0 |
| | 2020 | 2018 | BIOSTAGE, INC. | 84 OCTOBER HILL RD STE 11 | HOLLISTON | MA | 01746-1371 | MIDDLESEX | USA | R44HD095784 | A retrievable autologous bioengineered esophageal implant as a novel treatment for long-gap esophageal atresia | 000 | 1 | NIH | 1/23/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,103,346 ) |
| | 2019 | 2019 | BIOSTAGE, INC. | 84 OCTOBER HILL RD STE 11 | HOLLISTON | MA | 01746-1371 | MIDDLESEX | USA | R44HD095784 | A retrievable autologous bioengineered esophageal implant as a novel treatment for long-gap esophageal atresia | 000 | 2 | NIH | 10/26/2018 | $1,103,346 |
|
| Issue Date FY: 2018 ( Subtotal = $224,615 ) |
| | 2018 | 2018 | BIOSTAGE, INC. | 84 OCTOBER HILL RD STE 11 | HOLLISTON | MA | 01746-1371 | MIDDLESEX | USA | R44HD095784 | A retrievable autologous bioengineered esophageal implant as a novel treatment for long-gap esophageal atresia | 000 | 1 | NIH | 3/28/2018 | $224,615 |
|
|
